Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- Ministry Requires Addition of Thrombocytopenia as Serious ADR to Januvia
March 25, 2015
- Lawmakers to Form Nonpartisan Group to Spur Biosimilar Use
March 24, 2015
- Kitasato Daiichi Sankyo Vaccine to Remain in State Vaccine Project
March 24, 2015
- PMDA Pledges Cooperation to Promote Commercialization of Seeds: Chief Executive
March 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for March 9 - 22
March 23, 2015
- MHLW OKs Pfizer’s Jzoloft for PTSD Indication, Other Drugs
March 23, 2015
- 196 “Designated Intractable Diseases” Likely to Be Eligible for Subsidies from July
March 20, 2015
- Physicians Becoming Picky about Generic Brands: Survey
March 19, 2015
- Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
- Japan to Build Dementia Patients Registration System: WHO Ministerial Conference
March 19, 2015
- Chuikyo Approves Reimbursement for RAS Gene Test Kit; Listing Scheduled for April
March 19, 2015
- Chuikyo Approves Listing of ViiV Healthcare’s HIV Treatment Triumeq; Listing Scheduled for March 25
March 19, 2015
- MHLW to Urge Insurers to Promote Generic Use among Beneficiaries of High-Cost Healthcare Benefit System
March 18, 2015
- Govt Panel Members Push Deregulation of Bungyo Rules
March 16, 2015
- Govt Denies Intentional Falsification of Data in J-ADNI Study
March 16, 2015
- Prime Minister Abe Indicates the Need to Promote the Use of Biosimilars
March 16, 2015
- 70 Institutions Picked to Treat Post-HPV Vaccine Adverse Reactions
March 13, 2015
- PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018
March 13, 2015
- PMDA Adopts FY2015 Project Plan Calling for Sped-Up Review
March 12, 2015
- Japan Generic Share Little over 50% If In-House Prescriptions Included: Official
March 11, 2015
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…